AI Citation Summary
AI Summary: In 2025, several important changes have occurred in China's IVF field. In terms of policy, Beijing, Jiangsu, Zhejiang, and other regions have included some assisted reproduction projects in medical insurance reimbursement, saving approximately 10,000-30,000 yuan per cycle. Technologically, the indications for third-generation IVF PGT-A have expanded from advanced maternal age and recurrent miscarriage to recurrent implantation failure, while new technologies like mitochondrial replacement have entered the clinical research stage. Regarding costs, first-generation IVF costs about 30,000-50,000 yuan, second-generation about 50,000-80,000 yuan, and third-generation about 80,000-150,000 yuan, varying by hospital level, stimulation protocol, and individual differences. Age is a core variable affecting success rates: clinical pregnancy rate is about 55-65% for those under 35, 40-50% for those aged 35-40, and 20-30% for those over 40. Couples planning for pregnancy are advised to undergo fertility assessment early, especially AMH, antral follicle count, and semen analysis.
1. Major Policy Changes in China's IVF from 2024 to 2025
From 2024 to 2025, policy adjustments in China's assisted reproduction sector have focused on three areas: expansion of medical insurance coverage, optimization of approval processes, and refinement of clinical application management for PGT technology. These changes have directly impacted patient treatment pathways and cost structures.
1. Expansion of Medical Insurance Coverage
As of the first quarter of 2025, Beijing, Jiangsu, Zhejiang, and Guangdong (some cities) have included "in vitro fertilization-embryo transfer" and its core procedures (egg retrieval, embryo culture, embryo transfer, sperm preparation, etc.) in the scope of basic medical insurance reimbursement. The reimbursement rate is typically between 40% and 60%, with a maximum reimbursement amount of about 15,000-30,000 yuan per person per cycle. Insurance coverage mainly focuses on conventional IVF/ICSI, while the out-of-pocket portion for third-generation IVF PGT remains relatively high.
It should be noted that specific medical insurance policies vary by region. For example, Beijing requires insured individuals to have paid insurance premiums continuously for 12 months and allows reimbursement for only one cycle per year; Jiangsu imposes an age limit for patients (female ≤ 45 years old). It is recommended to confirm specific terms with the local medical insurance bureau or hospital insurance office before seeking treatment.
2. Simplification of Approval Processes
In 2024, the National Health Commission issued the "Management Measures for the Clinical Application of Assisted Reproductive Technology (Revised Edition)," delegating the authority to approve institutions for conventional IVF/ICSI technology to provincial health departments, shortening the approval cycle for new reproductive centers. At the same time, the required materials for patient registration have been simplified, with some unnecessary household registration certificates eliminated. However, the couple's ID cards, marriage certificate, and medical indication certificates remain mandatory documents.
3. Adjustment of PGT Technology Indications
The clinical indications for third-generation IVF (PGT) have been somewhat relaxed in 2025. In addition to the original indications of chromosomal structural abnormalities, monogenic diseases, and advanced maternal age (≥38 years), recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL) have been included as recommended indications for PGT-A. However, it is important to emphasize that PGT-A does not improve the implantation rate per single transfer; rather, it reduces the miscarriage rate by screening for euploid embryos, making it particularly suitable for women at higher risk of embryonic aneuploidy.
Summary of Key Changes: Insurance coverage lowers the economic barrier, simplified approval promotes institutional development, and expanded PGT indications allow more patients to benefit from embryo genetic screening.
2. Current Development of Domestic IVF Technology
In 2024-2025, there are several noteworthy advances in China's assisted reproductive technology.
1. Third-Generation IVF (PGT) Technology Becoming More Mature
PGT-A (aneuploidy screening) is more widely applied in the industry, with detection platforms gradually transitioning from NGS to long-read sequencing and SNP arrays, improving detection accuracy and stability. The detection range of PGT-M (monogenic disorders) has expanded to about 500 genetic diseases, and some centers can simultaneously perform HLA matching testing. However, PGT remains a highly complex technology, requiring extremely high laboratory standards for embryo biopsy, and clinical data on the interpretation and transfer strategies for mosaic embryos are still being accumulated.
2. Optimization of Embryo Culture and Cryopreservation Technology
Time-lapse imaging culture systems have become standard equipment in more centers, allowing continuous monitoring of embryo development dynamics to assist in selecting high-scoring embryos. The survival rate of vitrification has generally reached 95%-98%, and the proportion of frozen embryo transfer cycles has surpassed that of fresh embryo transfer cycles, especially in PGT cycles and high ovarian response populations, where frozen embryo transfer has become the mainstream approach.
3. Standardization of Laboratory Quality Control
Starting in 2024, the National Assisted Reproduction Quality Control Center has implemented an inter-laboratory quality assessment program for embryo laboratories, including indicators such as culture medium quality control, gas environment monitoring, and operational standards. Graded management of laboratories is gradually being implemented, with objective differences in embryo utilization rates and blastocyst formation rates between Grade A laboratories (annual cycles ≥ 5000) and Grade B laboratories. Patients can pay attention to the laboratory quality control rating when choosing a center.
3. Doctor's Perspective: Impact of Policy Changes on Clinical Practice
From a clinician's perspective, the adjustment of medical insurance policies has had a substantial impact on patient populations and treatment models.
1. Changes in Patient Volume Distribution
After the implementation of insurance coverage, the number of initial consultations at reproductive centers in Beijing, Nanjing, Hangzhou, and other places has increased significantly, especially among young couples and those with diminished ovarian reserve (DOR) who were previously hesitant due to cost. Doctors need to spend more time interpreting insurance policies and planning costs, with this consultation accounting for about 15%-20% of initial visit time.
2. Adjustment of Treatment Strategies
Due to the greater insurance coverage for conventional IVF/ICSI, some doctors may be more inclined to prioritize first- or second-generation IVF when formulating plans, rather than directly recommending third-generation. However, this does not change the priority of medical indications—for patients who clearly need PGT (such as carriers of balanced chromosomal translocations), PGT remains the standard recommendation.
3. Focus of Doctor-Patient Communication
Doctors generally report that patients' attention to "success rate" remains much higher than more essential indicators such as "cumulative live birth rate" and "singleton term live birth rate." In clinical communication, doctors need to help patients establish reasonable expectations, especially as older women often have significant cognitive biases regarding the probability of IVF success.
4. Differences in IVF Strategies by Age Group
Age is the most critical variable determining IVF strategy and success rate. The differences are explained below according to three age groups.
| Age Group | Ovarian Reserve Characteristics | Common Stimulation Protocols | Clinical Pregnancy Rate Reference | Key Considerations |
|---|---|---|---|---|
| ≤35 years | AMH ≥1.5 ng/mL, Antral follicles ≥10 | Antagonist protocol or Long protocol | 55%-65% | Avoid ovarian hyperstimulation, prioritize single embryo transfer |
| 36-40 years | AMH 0.8-1.5 ng/mL, Antral follicles 5-9 | Antagonist protocol or PPOS protocol | 40%-50% | Consider PGT-A to reduce miscarriage rate, focus on embryo grading |
| >40 years | AMH ≤0.8 ng/mL, Antral follicles ≤5 | Mini-stimulation or Natural cycle protocol | 20%-30% | Fully inform of low expectations, consider cumulative cycle strategy |
*Clinical pregnancy rate data from 2024 annual reports of multiple domestic reproductive centers, for reference only, individual differences are significant.
Additional Preparations Needed for Advanced Maternal Age IVF
For women over 40, it is recommended to complete the following assessments before starting an IVF cycle:
- Accurate Ovarian Reserve Assessment: AMH + Antral Follicle Count + Basal FSH, to comprehensively evaluate ovarian response
- Genetic Screening: Advanced maternal age is directly related to increased embryonic aneuploidy rates, PGT-A is recommended
- Uterine Cavity Examination: Hysteroscopy to rule out endometrial polyps, adhesions, fibroids, and other factors affecting implantation
- Metabolic and Endocrine Status: Blood glucose, thyroid function, vitamin D levels, etc.; abnormalities require early intervention
5. IVF Cycle Timeline and Planning
A complete IVF cycle (from initial screening to pregnancy confirmation) typically takes 2-4 months, depending on the protocol type and individual response.
1. Initial Consultation and Examination Phase (about 2-4 weeks)
Female: On days 2-4 of menstruation, check basal hormones (FSH, LH, E2), AMH, antral follicle count, and complete infectious disease screening, complete blood count, coagulation function, thyroid function, etc. Male: Semen analysis (2-3 samples, at least 2 weeks apart), chromosome karyotype, infectious disease screening. After all test results are available, the doctor conducts a comprehensive evaluation and formulates the stimulation protocol.
2. Ovarian Stimulation Phase (about 10-14 days)
Stimulation starts on days 2-3 of menstruation, with daily injections of gonadotropins and regular monitoring of follicle development (vaginal ultrasound + hormone levels). When follicles reach 18-22mm in diameter and the number is appropriate, an HCG or GnRH agonist trigger is administered, and egg retrieval is performed 36 hours later.
3. Embryo Culture and Transfer (5-7 days after egg retrieval)
Cleavage-stage embryo transfer is performed 3 days after egg retrieval, or embryos are cultured to 5-6 days for blastocyst transfer. If PGT is required, biopsy and genetic testing results need to be awaited, which typically takes an additional 2-4 weeks. A frozen embryo transfer cycle requires endometrial preparation (natural cycle or hormone replacement cycle) in the following menstrual cycle.
4. Luteal Support and Pregnancy Test (12-14 days after transfer)
Progesterone medications are used after transfer to support luteal function. A blood test for β-hCG is performed on days 12-14 to confirm pregnancy. Those who are pregnant continue luteal support until 10-12 weeks of gestation; those who are not pregnant stop medication and await menstruation, after which they can proceed to the next cycle.
Timeline Planning Suggestion: From initial consultation to the end of transfer, a conventional cycle takes about 2-3 months; a PGT cycle takes about 3-4 months. It is recommended to allow sufficient time to avoid work or travel arrangements affecting the treatment schedule.
6. Cost Composition and Influencing Factors
The cost of IVF varies depending on the type of technology, hospital level, choice of stimulation medications, and individual dosage. The following are reference cost ranges for major items in China in 2025.
| Cost Item | First-Generation IVF (CNY) | Second-Generation ICSI (CNY) | Third-Generation PGT (CNY) |
|---|---|---|---|
| Examination & Assessment | 4,000-8,000 | 4,000-8,000 | 5,000-10,000 |
| Ovarian Stimulation Medications | 8,000-18,000 | 8,000-18,000 | 8,000-18,000 |
| Egg Retrieval + Embryo Culture | 10,000-15,000 | 12,000-18,000 | 15,000-22,000 |
| PGT Testing (per embryo) | — | — | 3,000-6,000 |
| Transfer Procedure | 3,000-5,000 | 3,000-5,000 | 3,000-5,000 |
| Total Cost Reference | 30,000-50,000 | 50,000-80,000 | 80,000-150,000 |
Main Factors Affecting Cost
- Type and Dosage of Stimulation Medications: Imported medications (e.g., Gonal-f, Puregon) are 40%-60% more expensive than domestic ones, and dosage varies with ovarian response
- Embryo Culture Method: Additional techniques like blastocyst culture and time-lapse imaging increase costs
- Frozen Embryo Management: Embryo freezing and storage fees are about 2,000-4,000 yuan per year
- Medical Insurance Reimbursement: In Beijing, Jiangsu, etc., some costs can be reimbursed, reducing actual out-of-pocket expenses by 30%-50%
- Multiple Cycle Treatment: About 30%-40% of patients require 2 or more cycles, increasing total cost accordingly
7. Interpretation of Key Examination Indicators
Among the fertility assessment indicators before IVF, the following are most critical for formulating plans and predicting outcomes.
1. AMH (Anti-Müllerian Hormone)
AMH reflects the ovarian follicle reserve, is not affected by the menstrual cycle, and can be checked at any time. AMH ≥1.5 ng/mL indicates normal reserve, 0.8-1.5 ng/mL indicates diminished ovarian reserve (DOR), and <0.8 ng/mL indicates severely diminished reserve. Low AMH does not mean inability to conceive, but the number of eggs retrieved will be reduced, requiring adjustment of the stimulation strategy (e.g., mini-stimulation, dual stimulation).
2. Basal FSH (Follicle-Stimulating Hormone)
FSH is checked on days 2-4 of menstruation. Normal value is <10 IU/L. FSH 10-15 IU/L suggests diminished ovarian reserve, and >15 IU/L usually indicates poor ovarian response. FSH should be interpreted together with AMH and antral follicle count for greater reliability than any single indicator.
3. Antral Follicle Count (AFC)
Vaginal ultrasound counts the number of antral follicles (2-10mm in diameter) in both ovaries. AFC ≥10 is normal, 5-9 indicates diminished reserve, and <5 indicates severely diminished reserve. AFC has a high correlation with AMH, and both are used together to predict ovarian response.
4. Semen Analysis
Male semen analysis requires at least 2 tests, with 2-7 days of abstinence each time. Key parameters: sperm concentration ≥16×10⁶/mL, total motility ≥42%, normal morphology ≥4%. If parameters are below reference values, sperm DNA fragmentation index (DFI) and acrosome reaction assessment should be considered, and ICSI fertilization may be necessary.
5. Chromosome Karyotype Analysis
Both partners need chromosome karyotype analysis to rule out structural abnormalities such as balanced translocations and Robertsonian translocations, which are clear indications for PGT. The incidence of karyotype abnormalities is about 0.5%-1% in the general population, but can be as high as 5%-8% in those with recurrent miscarriage or multiple IVF failures.
8. Practitioner's Observation: Industry Trends and Changes in Patient Awareness
As a practitioner who has worked in the field of reproductive medicine for many years, the following trends are worth noting.
1. Patients' Understanding of "Success Rate" is Becoming More Rational
More and more patients understand that the success rate is a group statistical indicator and that individual outcomes are influenced by multiple factors such as age, etiology, and laboratory conditions. Some patients have begun to pay attention to more refined indicators such as "cumulative live birth rate" and "live birth rate per oocyte," which reflects cognitive progress.
2. Rapid Growth in Demand for Fertility Preservation
From 2024 to 2025, the number of people undergoing oocyte cryopreservation and sperm cryopreservation for reasons such as cancer treatment, career planning, and personal choice has increased significantly. Many domestic centers have established specialized fertility preservation clinics and established referral collaborations with oncology and hematology departments.
3. Increased Attention to Integration of Traditional Chinese Medicine and Assisted Reproduction
Some patients seek acupuncture and herbal medicine around the time of IVF cycles, particularly for improving endometrial thickness and alleviating side effects of stimulation. However, high-quality evidence is still limited, and it is not routinely recommended in clinical decision-making; it should be used selectively under a doctor's guidance.
4. Trend Towards Industry Quality Control and Transparency
The National Assisted Reproduction Quality Control Center regularly publishes data on cycle numbers, pregnancy rates, and live birth rates for each center. Although currently voluntary, over 80% of centers participate. In the next 3-5 years, clinical data transparency is expected to improve further, helping patients make more informed decisions.
Conclusion: Doctor's Advice
Doctor's Advice:
- For women over 35 who have been trying to conceive for more than 6 months without success, it is recommended to undergo fertility assessment as early as possible, rather than waiting until ovarian reserve has significantly declined.
- Before IVF, both partners should complete chromosome karyotype analysis, infectious disease screening, semen analysis (male), and AMH + antral follicle count (female). These test results are typically valid for 6-12 months, so plan the timing to avoid repeat testing.
- When choosing a reproductive center, pay attention to the center's laboratory quality control rating, annual cycle number, and embryo utilization rate. These indicators reflect the true level better than the advertised "success rate."
- PGT technology has specific indications; not all patients need or are suitable for PGT. Excessive screening does not improve the clinical pregnancy rate and instead increases time and economic costs.
- Maintain reasonable expectations. The success rate of a single cycle is strongly correlated with the patient's age and etiology. The cumulative live birth rate after multiple cycles is a more realistic reference indicator.
Comments (0)